Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized crossover trial of KVD900 for on-demand treatment of hereditary angioedema attacks
jRCT2051220178Phase 3Completed
- Sponsor
- KalVista Pharmaceuticals
- Start
- Apr 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of sebetralstat in hereditary angioedema (HAE) (3 arms), sponsored by KalVista Pharmaceuticals. Started Apr 2023; status: completed.
02
Drugs
sebetralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on jRCT2051220178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220178.